Corcept Therapeutics specializes in cortisol-modulating therapies, most notably commercializing Korlym (mifepristone) for the treatment of Cushing's syndrome. The enterprise also develops an advanced clinical pipeline of proprietary selective glucocorticoid receptor antagonists, including relacorilant (marketed as Lifyorli for platinum-resistant ovarian cancer and evaluated across various solid tumors), miricorilant for metabolic disorders like MASH, and dazucorilant for neurodegenerative diseases.